Cryo-Cell International financials
$4.05−2.64%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Nov 30 | FY24 Nov 30 | FY23 Nov 30 | FY22 Nov 30 | FY21 Nov 30 |
|---|---|---|---|---|---|
| Revenue | $31.6M | $32.0M | $31.3M | $30.3M | $28.9M |
| Gross profit | $24.2M | $24.0M | $23.0M | $21.5M | $19.9M |
| Gross margin | 76.6% | 75.2% | 73.2% | 71.0% | 68.9% |
| Operating income | $482.4K | $3.8M | -$12.3M | $4.0M | $4.0M |
| Net income | -$2.4M | $402.1K | -$9.5M | $2.8M | $2.1M |
| Net margin | −7.7% | 1.3% | −30.4% | 9.1% | 7.2% |
| Diluted EPS | $-0.30 | $0.05 | $-1.14 | $0.33 | $0.25 |
| EBITDA | $5.8M | $4.5M | $4.9M | $6.3M | $5.7M |
| Operating cash flow | $5.5M | $6.0M | $8.9M | $8.1M | $8.7M |
| Free cash flow | $5.2M | $3.6M | $2.1M | -$4.0M | $6.9M |
| Diluted shares | 8.1M | 8.2M | 8.3M | 8.5M | 8.4M |
Balance sheet
| Period end | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 |
|---|---|---|---|---|---|
| Cash & equivalents | $319.0K | $561.0K | $406.1K | $1.7M | $8.3M |
| Short-term investments | $3.0M | $2.9M | $574.2K | $17.6K | $75.4K |
| Total debt | $11.4M | $12.9M | $10.7M | $11.9M | $2.8M |
| Total assets | $61.7M | $64.7M | $61.2M | $64.9M | $60.7M |
| Total liabilities | $80.3M | $77.9M | $72.3M | $66.4M | $56.5M |
| Shareholders' equity | -$18.6M | -$13.2M | -$11.0M | -$1.5M | $4.2M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology